Transaction · 0001613084-26-000004

Doshi Dipal

Doshi Dipal, CEO, reported a transaction classified as withholding at Entrada Therapeutics, Inc. involving 8724.000000 shares for an estimated $62323.38. Reported holdings after the transaction were 517290.000000 shares. A 10b5-1 reference was not detected in the stored filing text.

withholdingSEC transaction code FCEO
TRDAEntrada Therapeutics, Inc.
Filing timeSep 03
Trade dateSep 02, 2026
Filing · SECView on SEC
InsiderProfile

Price performance since filing

Close on the filing date, the pre-filing context, and the forward return at standard windows
Price at filing
$7.17
Pre-filing
1mo ago1w ago1d ago -1.4%
Returns since
7d +0.0%30d +0.0%90d +0.0%180d +0.0%1y +0.0%

TRDA price since this filing

30 days of pre-filing context and vertical markers at the filing date plus 7d / 30d / 90d / 180d / 1y afterwards
TRDA since 2026-09-03Filed yesterday · 1 day of post-filing data
Loading…
Filing datePost-filing windows (7d, 30d, 90d, 180d, 1y)30 days of pre-filing context

Transaction facts

Stored Form 4 columns with their raw values

Non-derivative
Type
withholding
Code F
Identifier
0001613084-26-000004
Common Stock
Transaction date
Sep 02, 2026
Filed Sep 03, 2026, 09:19 PM · 1d delay
Shares
8.72k sh
$714 per share
Estimated value
-$6.23M
Computed from shares × price
Holdings after
517k sh
Direct

Filing signal explanations

Badges describe filing facts only — not predictions.

Cluster 14dRepeat 30dPattern $10.0MLarge $100M
Direct Ownership
-12score
Filing-only score

-12

Compact filing score computed from stored Form 4 facts. Version v1.

Mixed or weak signal

This filing has a negative filing-only score. It may be less informative as an insider-activity signal and needs extra context.

Reported relationships & other filings

Form 4 relationship flags and nearby filing context

Reported roles

CEO

Officer YesDirector Yes10% NoOther No
Footnotes & amended
  1. F1

    Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax wit…

  2. F2

    The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.97 to $7.34, inclusive. The reporting person undertakes to provide…

Original filing · 0001613084-26-000004
Related transactions

0 other filings

Same reporting owner
Recent company activity

0 recent txs

TRDA